Palatin Tech Stock Price, News & Analysis

Palatin Technologies (OTC PINK: PTNT) presented new preclinical data for its melanocortin agonists PL9654 and PL9655 at ARVO 2025, demonstrating promising results for treating diabetic retinopathy (DR). The compounds showed effectiveness in resolving inflammation, stabilizing blood-retinal barriers, reducing VEGF signaling, and protecting retinal ganglion cells. Key findings include vision preservation, inflammation control, retinal protection, and anti-angiogenic properties. Both compounds demonstrated efficacy through multiple administration routes, including topical delivery. This research is particularly significant as DR affects up to 80% of long-term diabetes patients, with CDC projecting U.S. cases to triple from 5.5 million in 2025 to 16 million by 2050. The melanocortin receptor system's role in regulating inflammation and tissue repair makes these compounds promising candidates for treating ocular diseases.

Palatin Technologies (OTC PINK: PTNT) has closed a reduced public offering, raising approximately $1.1 million through the sale of 7,324,119 shares of common stock at $0.15 per share, along with three series of warrants. The offering includes Series F warrants ($0.30 exercise price, 5-year expiry), Series G warrants ($0.15 exercise price, 24-month expiry), and Series H warrants ($0.225 exercise price, 24-month expiry from issuance). The company has transitioned to trading on the OTC Pink market and plans to use the proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners led the placement, with Laidlaw & Company as co-placement agent.

Palatin Technologies (OTC PINK: PTNT) presented breakthrough data from its Phase 3 MELODY-1 trial of PL9643 for Dry Eye Disease (DED) at ARVO 2025. The study demonstrated complete symptom resolution across multiple endpoints, with 6 of 13 symptom endpoints reaching statistical significance (p<0.05). PL9643 showed rapid onset of action starting at week 2 and continued improvement through week 12. The drug was well-tolerated with adverse event rates comparable to or better than vehicle. The DED market is projected to grow from $6.1 billion in 2024 to $7.5 billion by 2029. Following MELODY-1's success, Palatin plans two additional Phase 3 studies (MELODY-2 and MELODY-3), pending partnership and funding, with enrollment potentially starting in H2 2025 and topline data expected in H2 2026.

Palatin Technologies (PTN) has received a delisting notice from NYSE American due to its low stock price, resulting in immediate suspension of trading on the exchange. The company's shares will transition to trading on the OTC Pink Market under the symbol "PTNT" starting May 8, 2025.

The company plans to appeal the delisting decision by the deadline of May 14, 2025, though success is not guaranteed. CEO Carl Spana expressed disappointment but affirmed the company's commitment to advancing their business plan and increasing stockholder value. Palatin Technologies focuses on developing first-in-class medicines targeting the melanocortin receptor system.

Palatin Technologies (NYSE American: PTN) announced expected closure of an $11.5 million public offering on May 8, 2025, with potential for additional $11.5 million through milestone-related warrants. Combined with $2.3 million from April's ATM facility, this funding aims to resolve NYSE American's delisting notice due to non-compliance with stockholders' equity requirements. The company faces an appeal hearing later in Q2 2025. The financing will accelerate development of Palatin's obesity pipeline, including MC4R-targeted long-acting peptides and oral small molecules. The company plans to submit INDs in Q4 2025, with clinical data expected in H1 2026. Additionally, Palatin anticipates executing collaborations for its ocular portfolio, including a Phase 3 dry eye disease program and preclinical glaucoma and retina programs, in Q2 and Q3 2025.

Palatin Technologies (NYSE American: PTN) has announced the pricing of a public offering expected to raise up to $23 million. The offering includes 76,666,667 shares of common stock at $0.15 per share, along with three series of warrants (F, G, and H). The initial gross proceeds will be $11.5 million, with potential additional proceeds of up to $11.5 million if milestone-related Series G warrants are exercised. The offering includes participation from healthcare-focused institutional investors and company insiders, including the CEO, CFO, and board members. The funds will primarily support working capital and development of Palatin's obesity program. A.G.P./Alliance Global Partners is leading the placement, with Laidlaw & Company as co-placement agent. The offering is expected to close around May 8, 2025.

Palatin Technologies (NYSE American: PTN) presented new preclinical data for PL9588, their novel melanocortin receptor agonist, at the 2025 ARVO Annual Meeting. The data demonstrates PL9588's potential as a dual-action glaucoma therapy that both reduces intraocular pressure (IOP) and provides neuroprotection.

Key findings show that PL9588 increases fluid movement through the trabecular meshwork (p<0.05) and reduces retinal cell stress/death by ~25% in damaged retinas (p<0.05). The compound also decreased retinal ganglion cell death in an ischemia/reperfusion model (p<0.0001).

The global glaucoma market, valued at $5.71 billion in 2021, is projected to reach $9.77 billion by 2030. Glaucoma affects approximately 79.6 million people worldwide (2020) and is a leading cause of preventable vision loss.

Palatin Technologies announced breakthrough results from its Phase 3 MELODY-1 clinical trial for PL9643 in treating dry eye disease (DED). The drug achieved statistically significant complete symptom resolution across multiple endpoints - a first among dry eye therapies.

Key highlights:

• 6 out of 13 symptom endpoints showed significantly higher patient recovery with PL9643 vs placebo
• Symptom improvement started at week 2 and continued through week 12
• Treatment demonstrated better results than any FDA-approved DED therapy
• The drug showed excellent safety and tolerability

The company plans to conduct two more Phase 3 studies (MELODY-2 and MELODY-3) pending collaboration and funding. The dry eye disease market is projected to grow from $6.11 billion in 2024 to $7.46 billion by 2029. With 38 million Americans affected by DED but only 10% receiving prescription treatment, PL9643 represents a significant market opportunity.

Palatin Technologies (NYSE American: PTN) has announced positive appetite suppression results from its BMT-801 Phase 2 obesity study evaluating the co-administration of melanocortin 4 receptor (MC4R) agonist bremelanotide with GLP-1/GIP tirzepatide.

Key findings show significant improvements in appetite suppression across all treatment arms:

• Bremelanotide + tirzepatide: 71% increase
• Tirzepatide only: 73% increase
• Bremelanotide only: 71% increase

Notably, low-dose bremelanotide demonstrated effectiveness in preventing weight regain after tirzepatide discontinuation, while patients on tirzepatide alone regained over 50% of lost weight within two weeks of stopping treatment. The company plans to advance its next-generation MC4R agonists pipeline, with IND filings expected by Q4 2025 and initial clinical data in H1 2026.